Zasocitinib, Plaque Psoriasis, TYK2 Inhibitors, TAK-279, Dermatology

Zasocitinib: JH2 Selectivity, Phase 3 Efficacy, and the Road to Best-in-Class TYK2 Status in Plaque Psoriasis

Jitesh Rana, MD, Mo Elsafy, MD MSc, Beloo Mirakhur, MD PhD, Dr. Gina Ayala

31 Mar 2026 — 5 min read

Phase 3 LATITUDE data positions zasocitinib well above apremilast, while the pending NCT06973291 head-to-head trial against deucravacitinib will ultimately determine best-in-class standing among TYK2 inhibitors.

See Disclaimer below *

Plaque psoriasis affects approximately 7 million patients in the US, roughly 2.0 to 2.4 million of whom carry moderate-to-severe disease. Effective injectable biologics exist, yet a substantial portion of that population never reaches them. Needle phobia keeps many patients pre-biologic indefinitely. Others cycle through topical therapies without achieving adequate control. High-BMI patients and those with complex metabolic profiles frequently see blunted responses from traditional biologics. The result is a persistent adherence gap — and a real clinical opportunity for a safe, once-daily oral therapy capable of delivering biologic-grade efficacy.

Mechanism: Allosteric JH2 Targeting

The clinical case for zasocitinib (TAK-279 / NDI-034858) begins with its mechanism. Rather than broadly inhibiting JAK kinase activity, zasocitinib binds the JH2 pseudokinase domain allosterically, achieving >1,000,000-fold selectivity over other JAK family kinases. This structural precision is what separates zasocitinib from legacy pan-JAK inhibitors, which carry class-wide cardiovascular and thromboembolic liabilities. Zasocitinib carries no MACE (Major Adverse Cardiovascular Events) or VTE (Venous Thromboembolism) boxed warnings — a regulatory baseline that matters considerably for accessing the Line 2+ oral market.

Phase 3 LATITUDE: Efficacy Against Apremilast

The Phase 3 LATITUDE trials set a new efficacy benchmark for oral small molecules in plaque psoriasis. Against apremilast (Otezla), the current oral standard of care, the separation was clinically and statistically clear:

Clearance rates: Zasocitinib achieved up to 71.4% sPGA 0/1 versus 32.1% for apremilast (p < 0.001)
Depth of response: Up to 61.3% PASI 90 (near-complete clearance) and 33.4% PASI 100 (complete clearance) at Week 16
Speed of onset: Statistically significant separation from placebo by Week 4, addressing an early adherence barrier common with slower systemic agents

Safety Profile: Low Systemic Burden

The tolerability data removes several friction points that typically complicate provider adoption of systemic therapies. Traditional DMARDs require routine blood monitoring for hepatic and hematologic toxicity. Zasocitinib does not appear to share these liabilities:

🔬 Laboratory parameters: No Grade 3 or 4 transaminase elevations or significant CPK anomalies — removing the need for mandatory baseline and ongoing serological monitoring
🤢 Gastrointestinal tolerability: Unlike apremilast — which carries well-documented rates of nausea and diarrhea driving early discontinuation — zasocitinib shows minimal GI distress
📊 Overall TEAE rate: Treatment-emergent adverse events in 62.1% of patients, most rated mild to moderate in severity

Mucocutaneous Adverse Events: A Management Priority

Zasocitinib is not without adverse events. The clinical profile includes distinct TYK2 mechanism-related mucocutaneous signals that will require proactive management in clinical practice:

Aphthous ulcers: Mouth sores represent a recognized class effect for potent TYK2 inhibitors
Acneiform dermatitis: Follicular eruptions and acne-like rashes observed in active treatment arms
Upper respiratory tract infections (URIs): The most frequently reported mild TEAE across the development program

⚠️ None of these events drove meaningful discontinuation rates in the trial setting. Whether that holds in the real world will depend largely on how well providers anticipate and manage early-onset dermatologic flares.

The Deucravacitinib Head-to-Head: What the Data Needs to Show

The ongoing NCT06973291 trial comparing zasocitinib directly against Bristol Myers Squibb's deucravacitinib (Sotyktu) is the most consequential readout remaining in the development program. Deucravacitinib has first-mover advantage and established formulary presence. Non-inferiority will not be enough to shift prescribing behavior or justify clinical switching.

To claim best-in-class status, zasocitinib will need to demonstrate clear statistical superiority on:

PASI 90 at Week 16 and Week 52
PASI 100 at Week 16 and Week 52
Long-term durability, with no evidence of tachyphylaxis (loss of efficacy over time)

The 52-week extension data carries equal weight: health technology assessment bodies globally will require that data before making favorable pricing determinations.

Market Access: The Generic Apremilast Problem

Otezla currently generates approximately \$2.12B in US annual sales. Its impending loss of exclusivity will bring generic apremilast to market at low cost, and pharmacy benefit managers (PBMs) are likely to respond with step-therapy requirements — mandating that patients fail generic apremilast before authorizing coverage of next-generation oral agents.

Circumventing that dynamic will require value-based contracting (VBC):

Rebate guarantees: VBC frameworks tying PBM rebates to 16-week PASI 75 failure rates can make the financial case for preferred formulary access
Risk sharing: By absorbing the cost of non-responders, manufacturers can negotiate formulary placement that bypasses mandatory generic step-edits

Formulary Competition from Entrenched Biologics

The moderate-to-severe psoriasis market is not waiting around. Skyrizi holds an estimated 25% market share; Tremfya approximately 20%. Both benefit from deep volume-based rebating arrangements that make it difficult for novel mechanisms to gain preferred formulary placement without meaningful pricing concessions. The proliferation of Humira biosimilars has also compressed net pricing across immunology broadly, tightening the margin within which new entrants can compete on value.

Ex-US Pricing Headwinds

Global revenue projections need to reflect the scrutiny zasocitinib will face from health technology assessment bodies outside the US:

🇯🇵 Japan (PMDA/NHI): Biennial price revisions will erode net price over time, requiring volume to compensate
🇩🇪 Germany (AMNOG): The added-benefit assessment will compare zasocitinib against already-discounted legacy biologics — a comparison unlikely to yield a favorable rating without robust long-term data

The dependency on 52-week durability data is a structural vulnerability in this context. Any signs of late-stage efficacy erosion will accelerate downward pricing pressure across markets.

In-Class Competition: Envudeucitinib and Pipeline Fragmentation

The TYK2 inhibitor space is no longer a two-horse race. Alumis's envudeucitinib has recently posted competitive Phase 3 data. As additional selective TYK2 agents reach the market, clinical differentiation will become harder to sustain as a primary commercial argument. Competition will increasingly shift toward pricing power and portfolio leverage — favoring companies with broad immunology franchises capable of cross-indication bundle contracting with major US payers.

Out-of-Class Threat: Icotrokinra and the Oral IL-23 Question

The longer-term structural threat to zasocitinib's commercial position may not come from within the TYK2 class at all. Johnson \& Johnson's icotrokinra (JNJ-2113) is a first-in-class oral IL-23 receptor antagonist — a mechanism that entirely bypasses the JAK/STAT pathway.

If icotrokinra delivers the safety profile and efficacy depth of injectable IL-23 inhibitors in once-daily pill form, it:

Eliminates any residual provider or payer hesitation about TYK2 class effects
Positions itself above all oral JAK-pathway agents on formulary
Reframes the oral immunology competitive landscape entirely

That outcome is not guaranteed — but it represents the scenario zasocitinib's commercial strategy needs to plan around.

Disclaimer: ClinicalTrialsDaily.com is owned and operated by ClinRM LLC (“ClinRM”). The views and opinions expressed are solely those of the author(s) and are provided for educational and informational purposes only; they are not medical advice (or a substitute for professional medical judgment) and are not investment, legal, tax, or accounting advice, and nothing on this site is an offer, solicitation, or recommendation to buy or sell any security; information is provided “as is” without warranties of any kind and use is at your own risk—verify critical details with primary sources (e.g., trial registries, publications, and the study team). Full Disclaimer here.